* Advanced Mammography Systems Inc., of Wilmington, Mass., will install its FDA-cleared, MRI-based breast imaging system, called the Aurora, in the department of radiology at University of Arkansas for Medical Sciences, in Little Rock.

* Aurora Biosciences Corp., and Lidak Pharmaceuticals Inc., both of La Jolla, Calif., reported an agreement whereby Aurora receives an exclusive worldwide license, with rights to sublicense, Lidak's proprietary fluorescent, one-step, unbound free fatty acid determinator method for screening therapeutic compounds. Lidak retains rights for other fields, particularly diagnostic applications. The technology is based on a genetically engineered fluorescent probe that provides a unique method to directly measure unbound free fatty acid levels.

* Beacon Diagnostics Inc., of Foster City, Calif., signed a distributor agreement with Sejati Technical Services Sdn.Bhd., of Kuala Lumpur, Malaysia, covering the distribution of Beacon's OraScreen Rapid Test and future products to be developed by Beacon, including rapid, saliva-based, point-of-care diagnostic tests for hepatitis, other infectious diseases and cancers of the gastrointestinal tract, prostate, ovary and breast. Sejati will be granted exclusive distribution for these products in Malaysia, Singapore, Thailand, the Philippines, Vietnam and Indonesia. OraScreen is a multistep dipstick system for detection of antibodies to HIV in saliva.

* Biosite Diagnostics Inc., of San Diego,filed a premarket notification with the FDA seeking clearance to market the Triage Cardiac Panel, the first whole blood quantitative, point-of-care diagnostic for the rapid measurement of three biochemical markers used to aid in the diagnosis of acute myocardial infarction.

* Briana Bio-Tech Inc., of Edmonton, Canada, acquired the exclusive worldwide rights to Second Look, a breast cancer detection system, from Qualia Computing Inc., of Beavercreek, Ohio. Second Look is a computerized breast cancer detection system that can assist radiologists in the early diagnosis of breast cancer by enhancing their ability to interpret mammograms.

* International Murex Technologies Corp., of Toronto, has launched its E. Coli 0157 assay that has recently received an FDA license for sale in the U.S. The test uses a latex agglutination technology for the identification of Escherichia coli 0157.

* Perkin-Elmer Corp., of Norwalk, Conn., and its Applied Biosystems Division, of Foster City, Calif., reported a collaboration with Biometric Imaging, of Mountain View, Calif., to develop a high-throughput screening system for use by pharmaceutical research companies to accelerate the drug discovery process. The new system would enable the rapid, automated screening of drug candidates for their ability to bind to receptors on living cells.